Skip to content
Histamine phosphate, Ceplene(histamine dihydrochloride)
Ceplene (histamine dihydrochloride) is a small molecule pharmaceutical. Histamine dihydrochloride was first approved as Histamine phosphate on 1982-01-01. It is used to treat allergic rhinitis seasonal and urticaria in the USA. It has been approved in Europe to treat myeloid leukemia acute.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
respiratory tract diseasesD012140
otorhinolaryngologic diseasesD010038
skin and connective tissue diseasesD017437
immune system diseasesD007154
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Histamine phosphate
Tradename
Company
Number
Date
Products
HISTAMINE PHOSPHATEEli LillyN-000734 DISCN1982-01-01
3 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
allergic rhinitis seasonalEFO_0003956D006255J30
urticariaEFO_0005531D014581L50
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L03: Immunostimulants
— L03A: Immunostimulants
— L03AX: Other immunostimulants in atc
— L03AX14: Histamine dihydrochloride
HCPCS
No data
Clinical
Clinical Trials
45 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myeloid leukemia acuteD015470C92.0———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Knee osteoarthritisD020370EFO_0004616M17——1——1
NeoplasmsD009369C80——1——1
MelanomaD008545——1——1
LeukemiaD007938C95——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypersensitivityD006967EFO_0003785T78.4011——24
Allergic rhinitisD065631J30.921——24
Allergic rhinitis seasonalD006255EFO_0003956J30—2———2
Myelodysplastic syndromesD009190D4611———1
Myelomonocytic leukemia chronicD015477C93.111———1
Allergic conjunctivitisD003233EFO_0007141H10.44—1———1
Multiple sclerosisD009103EFO_0003885G35—1———1
Kidney neoplasmsD007680EFO_0003865C64—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AsthmaD001249EFO_0000270J451———34
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PruritusD011537HP_0000989L29————1212
Peptic ulcerD010437HP_0004398K27————22
NeuralgiaD009437EFO_0009430————11
Skin diseasesD012871L00-L99————11
Acute painD059787R52————11
Food hypersensitivityD005512EFO_1001890————11
Diet therapyD004035————11
Chronic urticariaD000080223L50.8————11
Bronchial diseasesD001982————11
CoughD003371HP_0012735R05————11
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameHISTAMINE DIHYDROCHLORIDE
INN—
Description
Histamine dihydrochloride (INN, trade name Ceplene) is a salt of histamine that is used as a drug for the prevention of relapse in patients diagnosed with acute myeloid leukemia (AML).
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cl.Cl.NCCc1c[nH]cn1
Identifiers
PDB—
CAS-ID56-92-8
RxCUI142136
ChEMBL IDCHEMBL1533310
ChEBI ID—
PubChem CID5818
DrugBankDBSALT002193
UNII ID—
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,491 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
2,927 adverse events reported
View more details